Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 15/20 | 0.80 |
| ▸ | KDR | P35968 | 1/20 | 0.58 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.53 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 0.53 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.53 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.51 |
| ▸ | GSK3A | P49840 | 1/20 | 0.51 |
| ▸ | PIM1 | P11309 | 1/20 | 0.51 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.49 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4657338 | 0.92 | BRAF (0.81) | BRAFKDRMAPK13MARK2LIMK1 | |
| SCHEMBL4657124 | 0.91 | BRAF (0.80) | BRAFKDRMAPK13MARK2LIMK1 | |
| SCHEMBL4655927 | 0.90 | BRAF (0.79) | BRAFKDRMAPK13MARK2LIMK1 | |
| SCHEMBL4655862 | 0.90 | BRAF (0.81) | BRAFKDRMAPK13MARK2LIMK1 | |
| SCHEMBL5622917 | 0.90 | BRAF (0.76) | BRAFKDRMAPK13MARK2LIMK1 | |
| SCHEMBL4655971 | 0.90 | BRAF (0.78) | BRAFKDRMAPK13MARK2LIMK1 | |
| SCHEMBL4657053 | 0.90 | BRAF (0.78) | BRAFKDRMAPK13MARK2LIMK1 | |
| SCHEMBL4656069 | 0.90 | BRAF (0.78) | BRAFKDRMAPK13MARK2LIMK1 | |
| SCHEMBL4657269 | 0.89 | BRAF (1.00) | BRAFKDR | |
| SCHEMBL4655934 | 0.89 | BRAF (0.76) | BRAFKDRMAPK13MARK2LIMK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219186-A1 | Pyrazolo[1,5-A]pyrimidine derivatives and methods of use thereof | WYETH (US) | 2007-09-20 | — | — | US | claimed |
| EP-1996594-A2 | PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007109093-A2 | PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF | WYETH (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070219186-A1 | Pyrazolo[1,5-A]pyrimidine derivatives and methods of use thereof | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219186-A1 | Pyrazolo[1,5-A]pyrimidine derivatives and methods of use thereof | DPYD, TYMP, TYMS | BRAF 289/4885KDR 3374/4885MAPK13 3288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.